AYTU - Aytu BioScience, Inc.

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
0.579900
+0.019900 (+3.553576%)
As of 10:28AM EDT. Market open.
Stock chart is not supported by your current browser
Previous Close0.560000
Open0.560000
Bid0.575500 x 300
Ask0.579900 x 200
Day's Range0.560000 - 0.590000
52 Week Range0.380000 - 15.800000
Volume515,565
Avg. Volume2,615,454
Market Cap18.048M
Beta3.22
PE Ratio (TTM)N/A
EPS (TTM)-12.756000
Earnings DateFeb 7, 2018 - Feb 12, 2018
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est10.00
Trade prices are not sourced from all markets
  • ACCESSWIRE23 days ago

    Aytu BioScience to Present at The MicroCap Conference on April 10th in New York City at the Essex House

    ENGLEWOOD, CO / ACCESSWIRE / April 3, 2018 / Aytu BioScience, Inc. (NASDAQ: AYTU) (the "Company") will be presenting at this year's MicroCap Conference on Tuesday, April 10, 2018 at 10:30 am. ...

  • ACCESSWIRE29 days ago

    Aytu BioScience Announces Exercise of Underwriters' Over-Allotment Option

    ENGLEWOOD, CO / ACCESSWIRE / March 28, 2018 / Aytu BioScience, Inc. (NASDAQ: AYTU) (the "Company"), a specialty life sciences company focused on global commercialization of novel products in ...

  • ACCESSWIRElast month

    Aytu BioScience Presents New Research Findings for Natesto(R) at the Endocrine Society's 100th Annual Meeting

    Post-hoc Data Analysis Demonstrates Natesto's Restoration of Normal Testosterone Levels in Hypogonadal Men While Maintaining Normal Levels of Estradiol (E2) and Dihydrotestosterone (DHT), Which Are Frequently ...

  • Has Aytu BioScience Inc (NASDAQ:AYTU) Improved Earnings Growth In Recent Times?
    Simply Wall St.2 months ago

    Has Aytu BioScience Inc (NASDAQ:AYTU) Improved Earnings Growth In Recent Times?

    Today I will take a look at Aytu BioScience Inc’s (NASDAQ:AYTU) most recent earnings update (31 December 2017) and compare these latest figures against its performance over the past fewRead More...

  • Aytu BioScience Receives Market Registration for the MiOXSYS® System for Male Infertility in Mexico
    PR Newswire2 months ago

    Aytu BioScience Receives Market Registration for the MiOXSYS® System for Male Infertility in Mexico

    ENGLEWOOD, Colo., March 7, 2018 /PRNewswire/ -- Aytu BioScience, Inc. (AYTU), a specialty life sciences company focused on global commercialization of novel products in the field of urology, today announced that it has received registration in Mexico for the MiOXSYS System, from the Secretary of Health at Comisión Federal para la Protección contra Riesgos Sanitarios (COFEPRIS).  The MiOXSYS System will be distributed exclusively through IMP Medica, a distributor of medical products to urologists, andrologists, and fertility centers throughout Mexico and in key markets in Latin America. Josh Disbrow, Chief Executive Officer of Aytu BioScience, commented, "Regulatory licenses and registrations are critical to our efforts of effectively penetrating these new markets.

  • Aytu BioScience Announces Closing of $12,000,000 Public Offering
    PR Newswire2 months ago

    Aytu BioScience Announces Closing of $12,000,000 Public Offering

    ENGLEWOOD, Colo., March 6, 2018 /PRNewswire/ -- Aytu BioScience, Inc. (AYTU) (the "Company"), a specialty life sciences company focused on global commercialization of novel products in the field of urology, today announced the closing of its previously announced underwritten public offering for total gross proceeds of $12,000,000, before deducting underwriting discounts, commissions and other offering expenses payable by the Company. The securities offered by the Company consist of (i) Class A Units consisting of an aggregate of 19,520,000 shares of our Common Stock and Warrants to purchase an aggregate of 19,520,000 shares of Common Stock, at a public offering price of $0.45 per Class A Unit, and (ii) Class B Units consisting of 3,216 shares of our Series B Convertible Preferred Stock, with a stated value of $1,000, and convertible into an aggregate of 7,146,667 shares of Common Stock, and Warrants to purchase an aggregate of 7,146,667 shares of Common Stock, at a public offering price of $1,000 per Class B Unit.

  • Zynex Appoints New Independent Board Member
    PR Newswire2 months ago

    Zynex Appoints New Independent Board Member

    ENGLEWOOD, Colo., March 6, 2018 /PRNewswire/ -- Zynex, Inc. (ZYXI), an innovative medical technology company specializing in the manufacture and sale of non-invasive medical devices for pain management, stroke rehabilitation, cardiac monitoring and neurological diagnostics, today announced the appointment of Joshua R. Disbrow to its Board of Directors and Audit Committee. Mr. Disbrow has been in the life sciences industry for over twenty years across pharmaceuticals, diagnostics, and medical devices. Currently, Mr. Disbrow serves as the Chairman and Chief Executive Officer of Aytu BioScience, Inc. ("Aytu" NASDAQ: AYTU), a commercial-stage specialty life sciences company focused on global commercialization of novel products in the field of urology.  Prior to forming Aytu, Mr. Disbrow was the Chief Operating Officer of Ampio Pharmaceuticals ("Ampio", a NASDAQ traded company) and led the Luoxis Diagnostics subsidiary "Luoxis").

  • GlobeNewswire2 months ago

    Tauriga Sciences Inc. Acquires Equity Stake in Colorado based NASDAQ Listed Biotechnology Firm Focused in the Medical Field of Urology

    NEW YORK, NY, March 02, 2018-- Tauriga Sciences, Inc., engaged in building its business through the development, distribution, and licensing of proprietary products as well as the evaluation of potential ...

  • Aytu BioScience Announces Pricing of $12,000,000 Public Offering
    PR Newswire2 months ago

    Aytu BioScience Announces Pricing of $12,000,000 Public Offering

    ENGLEWOOD, Colo., March 1, 2018 /PRNewswire/ -- Aytu BioScience, Inc. (AYTU) (the "Company"), a specialty life sciences company focused on global commercialization of novel products in the field of urology, today announced the pricing of an underwritten public offering with expected total gross proceeds of $12,000,000, before deducting underwriting discounts, commissions and other offering expenses payable by the Company. The securities offered by the Company consist of (i) Class A Units consisting of an aggregate of 19,520,000 shares of our Common Stock and Warrants to purchase an aggregate of 19,520,000 shares of Common Stock, at a public offering price of $0.45 per Class A Unit, and (ii) Class B Units consisting of 3,216 shares of our Series B Convertible Preferred Stock, with a stated value of $1,000, and convertible into an aggregate of 7,146,667 shares of Common Stock, and Warrants to purchase an aggregate of 7,146,667 shares of Common Stock, at a public offering price of $1,000 per Class B Unit.

  • Aytu BioScience Provides Update on the Continued Growth of Natesto® in the U.S.
    PR Newswire2 months ago

    Aytu BioScience Provides Update on the Continued Growth of Natesto® in the U.S.

    ENGLEWOOD, Colo., Feb. 21, 2018 Aytu BioScience, Inc. (AYTU), a specialty life sciences company focused on global commercialization of novel products in the field of urology, today provided an update on the ongoing launch of Natesto in the U.S.  Robust Natesto prescription growth continued through January 2018, with total prescriptions reaching 1,094, their highest level to date and demonstrating 300% growth over the same month last year.  Additionally, for the three months ending January 31, 2018 Natesto prescriptions increased 12% over the three-month period ending October 31, 2017. Natesto total prescriptions for the month of January were 1,094, the highest monthly total recorded to date.

  • Benzinga2 months ago

    Moleculin Biotech's Volatility, Explained

    Moleculin Biotech Inc (NASDAQ: MBRX )’s good-news rally had a short life. The stock popped 55 percent Thursday after management announced a “breakthrough” discovery of a molecule capable of shutting down ...

  • Aytu BioScience Provides Fiscal Second Quarter 2018 Business Update - Live Conference Call and Webcast Today at 4:30 pm ET
    PR Newswire3 months ago

    Aytu BioScience Provides Fiscal Second Quarter 2018 Business Update - Live Conference Call and Webcast Today at 4:30 pm ET

    Natesto prescriptions increased 23% over previous quarter, and 317% over the same quarter last year ENGLEWOOD, Colo. , Feb. 8, 2018 /PRNewswire/ -- Aytu BioScience, Inc. (NASDAQ: AYTU), a specialty life ...

  • Aytu BioScience to Report Fiscal Second Quarter 2018 Results and Business Update
    PR Newswire3 months ago

    Aytu BioScience to Report Fiscal Second Quarter 2018 Results and Business Update

    ENGLEWOOD, Colo., Feb. 1, 2018 /PRNewswire/ -- Aytu BioScience, Inc. (AYTU), a specialty life sciences company focused on global commercialization of novel products in the field of urology, today announced that the Company will present its operational results for the fiscal second quarter 2018 on Thursday, February 8, 2018, at 4:30 p.m. ET.  The Company will review recent accomplishments and provide an overview of its business and growth strategy. The webcast will be accessible live and archived on Aytu BioScience's website, within the Investors section under Corporate Presentations & Media, at aytubio.com, for 90 days. Aytu BioScience is a commercial-stage specialty life sciences company focused on global commercialization of novel products in the field of urology, with a focus on products addressing vitality, sexual wellness, and reproductive health.

  • OTC Markets Group Announces Quarterly Index Performance and Rebalancing
    PR Newswire3 months ago

    OTC Markets Group Announces Quarterly Index Performance and Rebalancing

    NEW YORK , Jan. 16, 2018 /PRNewswire/ --   OTC Markets Group Inc. (OTCQX: OTCM), operator of financial markets for 10,000 U.S. and global securities, today announced the fourth quarter 2017 performance ...

  • Is Aytu BioScience Inc’s (NASDAQ:AYTU) Liquidity As Good As Its Solvency?
    Simply Wall St.4 months ago

    Is Aytu BioScience Inc’s (NASDAQ:AYTU) Liquidity As Good As Its Solvency?

    Aytu BioScience Inc (NASDAQ:AYTU), which has zero-debt on its balance sheet, can maximize capital returns by increasing debt due to its lower cost of capital. However, the trade-off is AYTURead More...

  • Aytu BioScience to Present at Biotech Showcase 2018 Investor Conference
    PR Newswire4 months ago

    Aytu BioScience to Present at Biotech Showcase 2018 Investor Conference

    Aytu's management will present on Tuesday, January 9th at 9:30 AM PT in Yosemite-C (Ballroom level) and will be meeting with investors throughout the conference. Aytu BioScience is a commercial-stage specialty life sciences company focused on global commercialization of novel products in the field of urology, with a focus on products addressing vitality, sexual wellness, and reproductive health. The Company currently markets two prescription products in the U.S.: Natesto®, the first and only FDA-approved nasal formulation of testosterone for men with hypogonadism (low testosterone, or "Low T") and ProstaScint® (capromab pendetide), the only FDA-approved imaging agent specific to prostate specific membrane antigen (PSMA) for prostate cancer detection and staging.

  • PR Newswire4 months ago

    Aytu BioScience Announces Appointment of David Green as Chief Financial Officer

    ENGLEWOOD, Colo., Dec. 18, 2017 /PRNewswire/ -- Aytu BioScience, Inc. (AYTU), a specialty life sciences company focused on global commercialization of novel products in the field of urology, today announced the appointment of David A. Green as Chief Financial Officer.  Mr. Green is a highly accomplished CFO, who brings an extensive array of financial, accounting, and operational experience to Aytu, including a background at both public and private life sciences companies over his twenty-five-year career.  Effective today Mr. Green joins Aytu BioScience to oversee the Company's finance and accounting functions, and will report directly to the Chief Executive Officer. Prior to joining Aytu BioScience, Mr. Green served as Chief Accounting Officer at Intarcia Therapeutics, a biopharmaceutical company currently engaged in late stage clinical development.  Prior to that, he was Chief Financial Officer of Catheter Connections, a commercial-stage medical device company that was acquired by Merit Medical.

  • Aytu BioScience Inc (AYTU): Has Recent Earnings Growth Beaten Long-Term Trend?
    Simply Wall St.5 months ago

    Aytu BioScience Inc (AYTU): Has Recent Earnings Growth Beaten Long-Term Trend?

    Measuring Aytu BioScience Inc’s (NASDAQ:AYTU) track record of past performance is a useful exercise for investors. It enables us to understand whether or not the company has met or exceedRead More...

  • ACCESSWIRE5 months ago

    Aytu BioScience, Inc. to Present at the 10th Annual LD Micro Main Event

    LOS ANGELES, CA / ACCESSWIRE / November 29, 201 7 / Aytu BioScience, Inc. (NASDAQ: AYTU), a specialty life sciences company focused on global commercialization of novel products in the field of urology, ...

  • Aytu BioScience, Inc. :AYTU-US: Earnings Analysis: Q1, 2018 By the Numbers : November 28, 2017
    Capital Cube5 months ago

    Aytu BioScience, Inc. :AYTU-US: Earnings Analysis: Q1, 2018 By the Numbers : November 28, 2017

    Categories: Yahoo FinanceGet free summary analysis Aytu BioScience, Inc. reports financial results for the quarter ended September 30, 2017. We analyze the earnings along side the following peers of Aytu BioScience, Inc. – Career Education Corporation, Capella Education Company and Cambium Learning Group, Inc. (CECO-US, CPLA-US and ABCD-US) that have also reported for this period. Highlights Summary ... Read more (Read more...)

  • Aytu BioScience Provides Update on the Continued Growth of Natesto® in the U.S.
    PR Newswire5 months ago

    Aytu BioScience Provides Update on the Continued Growth of Natesto® in the U.S.

    ENGLEWOOD, Colo., Nov. 28, 2017 /PRNewswire/ -- Aytu BioScience, Inc. (AYTU), a specialty life sciences company focused on global commercialization of novel products in the field of urology, today provided an update on the launch of Natesto in the U.S.  Significant Natesto prescription growth continued through October 2017, with prescriptions increasing 17% from the previous month, reaching their highest levels to date.  Additionally, in October, the number of physicians prescribing Natesto increased 16% from the previous month.

  • Aytu BioScience Provides Fiscal First Quarter 2018 Business Update - Live Conference Call and Webcast Today at 4:30 pm ET
    PR Newswire6 months ago

    Aytu BioScience Provides Fiscal First Quarter 2018 Business Update - Live Conference Call and Webcast Today at 4:30 pm ET

    ENGLEWOOD, Colo. , Nov. 9, 2017 /PRNewswire/ -- Aytu BioScience, Inc. (NASDAQ: AYTU), a specialty life sciences company focused on global commercialization of novel products in the field of urology, today ...

  • Aytu BioScience Receives Market Approval from the Australian Therapeutic Goods Administration for the MiOXSYS® System for Male Infertility
    PR Newswire6 months ago

    Aytu BioScience Receives Market Approval from the Australian Therapeutic Goods Administration for the MiOXSYS® System for Male Infertility

    ENGLEWOOD, Colo., Nov. 7, 2017 /PRNewswire/ -- Aytu BioScience, Inc. (AYTU), a specialty life sciences company focused on global commercialization of novel products in the field of urology, today announced that the Australian Government Department of Health and Therapeutic Goods Administration (TGA) has approved the MiOXSYS® System for inclusion on the Australian Register of Therapeutic Goods. Josh Disbrow, Chief Executive Officer of Aytu BioScience, commented, "MiOXSYS continues to gain traction with its international commercial expansion as regulatory bodies, like Australia's TGA, approve the product for clinical use in the assessment of male infertility. In Australia, approximately one in six couples suffer from infertility, and almost half of these cases can be attributed to male factor infertility.

  • Aytu BioScience to Report Fiscal First Quarter 2018 Results and Business Update
    PR Newswire6 months ago

    Aytu BioScience to Report Fiscal First Quarter 2018 Results and Business Update

    ENGLEWOOD, Colo., Nov. 2, 2017 /PRNewswire/ -- Aytu BioScience, Inc. (AYTU), a specialty life sciences company focused on global commercialization of novel products in the field of urology, today announced that the Company will present its operational results for the fiscal first quarter 2018 on Thursday, November 9, 2017, at 4:30 p.m. ET.  The Company will review recent accomplishments and provide an overview of its business and growth strategy. The webcast will be accessible live and archived on Aytu BioScience's website, within the Investors section under Corporate Presentations & Media, at aytubio.com, for 90 days. Aytu BioScience is a commercial-stage specialty life sciences company focused on global commercialization of novel products in the field of urology, with a focus on products addressing vitality, sexual wellness, and reproductive health.

  • Aytu BioScience Presents Clinical Findings for its MiOXSYS® System at 73rd Annual Meeting of the American Society of Reproductive Medicine
    PR Newswire6 months ago

    Aytu BioScience Presents Clinical Findings for its MiOXSYS® System at 73rd Annual Meeting of the American Society of Reproductive Medicine

    ENGLEWOOD, Colo. , Nov. 1, 2017 /PRNewswire/ -- Aytu BioScience, Inc. (NASDAQ: AYTU), a specialty life sciences company focused on global commercialization of novel products in the field of urology, today ...